Alzheimer Disease Clinical Trial
— HIADOfficial title:
Hearing Intervention for Patients With Early-Stage Alzheimer's Disease: Determining the Benefits for Patients and Family Caregivers
Verified date | April 2017 |
Source | Phonak AG, Switzerland |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
There is a strong connection between hearing loss and cognitive impairment, particularly dementia, in old age. Worldwide, dementia affects approximately 5% of persons over the age of 65 years. Hearing loss is even more prevalent in old age, affecting an estimated one third of persons over the age of 65 years. Thus, there is likely a large degree of overlap between the impairments. Indeed, this overlap may influence older adults' everyday functioning, communication, social engagement and quality of life, as well as influencing the well-being of their family caregivers. This project will examine whether patients with hearing loss and Alzheimer's disease, the most common form of dementia, derive benefit the from hearing aids prescribed and fit to them following current best practice procedures in a geriatric audiology clinic. For the first time, a formal evaluation of the potential benefits of hearing aids for the patients' family caregivers will also be conducted.
Status | Completed |
Enrollment | 25 |
Est. completion date | February 2017 |
Est. primary completion date | February 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years and older |
Eligibility |
Inclusion Criteria: - Referred to the Audiology department by a physician with a confirmed diagnosis of Alzheimer's disease (or no diagnosis of AD if a normal cognition participant) - Pure-tone threshold at 3 kHz in excess of 35 dB HL in the worse ear - 60 years of age or older - Able to read and communicate well in English - Allow the researchers access to their medication list throughout the study to assess any changes in medications - Willing to use one or more hearing aid(s) on a regular basis - Has a caregiver who… - Is a family member - Is over the age of 18 - Is able to read and communicate well in English. - Accompanies participant to Baycrest for all necessary appointments - Provides qualitative and quantitative assessments of the participant's everyday behaviours and functioning - Is willing to learn and support the participant in using hearing aid(s), provide information on their own well-being and communication function - If they currently use one or more hearing aid(s), have acquired said aid(s) at least one year prior and are using it/them in a stable fashion. Exclusion Criteria: - Suffered a traumatic brain injury or stroke within the past five years - Has a history of untreated psychiatric illness - Has an uncorrected deficit in visual acuity or an untreated visual medical issue (e.g., glaucoma, macular degeneration, diabetic retinopathy) - Suffers from a neurological disorder (e.g., multiple sclerosis, epilepsy) - Has any untreated medical conditions that could jeopardize participation in the study - Has been taking medication for their cognitive impairment (e.g., cholinesterase inhibitor, NMDA receptor antagonists) for less than one month. - Has a caregiver who… - Is not cognitively stable (e.g., has been diagnosed with mild cognitive impairment or dementia) - Has a terminal medical or untreated psychiatric conditions that could jeopardize their participation in the study. |
Country | Name | City | State |
---|---|---|---|
Canada | Baycrest Center of Geriatric Care | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Phonak AG, Switzerland | Baycrest Centre for Geriatric Care, University of Toronto |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Client Oriented Scale of Improvement (COSI): Change over 3months | Measure of communication situations where the participant experiences difficulty (e.g., at church, in a noisy restaurant). Charts change in difficulty over time | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Primary | Hearing Handicap Inventory of the Elderly (HHIE): Change over 3months | Measure of hearing and communication handicap | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Primary | International Outcome Inventory for Hearing Aids (IOI-HA): Change over 2months | Measure of the effectiveness of hearing aid treatments | 1st, 3rd month for AD_HI & NC_HI (4th, 6th month for controls AD_WaitC & AD_ActC resp.) | |
Primary | Self-Assessment of Communication (SAC): Change over 3months | Measure of difficulties caused by an individual's hearing los | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Primary | Satisfaction with Amplification in Daily Life (SADL): Change over 2months | Measure of satisfaction with using hearing aids | 1st, 3rd month for AD_HI & NC_HI (4th, 6th month for controls AD_WaitC & AD_ActC resp.) | |
Primary | Significant Other Assessment of Communication (SOAC): Change over 3months | Completed by significant other, measure of a communication partner's hearing difficulties | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Primary | Significant Other Scale for Hearing Disability (SOS-Hear): Change over 3months | Measure of third-party disability experienced by spouses of older people with hearing impairment | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Secondary | Words-in-noise test (WIN): Change over 3months | Determines the signal-to-noise (SNR) threshold at which the person can correctly recognize 50% of the target words | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Secondary | Dichotic digits test (DDT): Change over 3months | Measure of central auditory processing | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Secondary | Montreal Cognitive Assessment (MoCA): Change over 3months | Measure of cognitive status | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Secondary | Hopkins Verbal-Learning Test (HVLT): Change over 3months | Measure of verbal memory | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Secondary | Brief Visuospatial Memory Test-R (BVMT): Change over 3months | Measure of visual memory | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Secondary | Behavioural Pathology in Alzheimer's disease (BEHAVE-AD): Change over 3months | Measure of problem behaviours demonstrated by individuals with dementia | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Secondary | Neuropsychiatric Inventory Brief (NPI-Q): Change over 3months | Measure of 12 neuropsychiatric symptoms commonly experienced by individuals with dementia | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Secondary | Positive and Negative Affect Schedule (PANAS): Change over 3months | Measure of mood assessing frequency of 10 positive and 10 negative emotions | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Secondary | Geriatric Depression Scale- Short Form (GDS-S): Change over 3months | Measure of depression in older adults | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Secondary | Bristol Activities of Daily Living Scale: Change over 3months | Measure of instrumental and basic activities of daily living over the past two weeks | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Secondary | Activity and Social Participation Assessment: Change over 3months | Measure of the frequency of specific activities | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Secondary | Quality of Life in Alzheimer's disease: Change over 3months | Measure of the domains of physical health, energy, mood, living situation, memory, family, marriage, friends, chores, fun, money, self, and life as a whole | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Secondary | Practical Hearing Test- Revised: Change over 2months | Measure of objective ability to use hearing aids | 1st, 3rd month for AD_HI & NC_HI (4th, 6th month for controls AD_WaitC & AD_ActC resp.) | |
Secondary | Measure of Audiologic Rehabilitation Self-Efficacy for Hearing Aids: Change over 3months | Measure of ability to use and maintain hearing aid | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Secondary | Perception of Conversation Index- Dementia of the Alzheimer Type: Change over 3months | Measure of caregivers' strategies for overcoming conversation difficulties | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Secondary | Relationship Satisfaction Questionnaire (RAS): Change over 3months | Measure of satisfaction with primary relationship | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Secondary | Social Support Questionnaire: Change over 3months | Measure of level of social support | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Secondary | Zarit Burden Interview- Short Form: Change over 3months | Measure of burden associated with behavioural impairments and the situation at home | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Secondary | Short-Form Health Survey-12 items: Change over 3months | Measure of functional health and well-being | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) | |
Secondary | Hours of hearing aid use: Change over 3months | Measure of how many hours the participant is wearing their hearing aid daily | 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |